Bioinformatic Analysis of Epigenomic Studies for Major Depressive Disorder
DOI:
https://doi.org/10.31157/an.v27i2.326Keywords:
Epigenomics, DNA Methylation, Psychiatric Genomics, Bioinformatics, Major depressive disorderAbstract
Background: Major depressive disorder (MDD) is a common psychiatric entity, being characterized by alterations in mood and in other clinical dimensions. Several epigenome-wide association studies (EWAS) for MDD have been published. Here, we aimed to identify common genes in EWAS and their convergence with multiple lines of genomic evidence. Methods: We carried out a computational analysis using data of EWAS, which included a meta-analysis for brain samples of MDD, a convergence analysis for brain and blood samples, and top results from available genome-wide expression and association data. Functional enrichment and protein-protein interaction network analyses were also done. Results: The meta-analysis for brain samples detected a significant gene, FAM53B. A list of forty-four top differentially methylated (DM) candidate genes was found, including GRM8, NOTCH4 and SEMA6A, in addition to known druggable genes. The binding-sites for brain-expressed transcription factors, CREB and FOXO1, were enriched in the top DM genes. The protein-protein interaction networks showed that DM genes for MDD, such as RPRM and TMEM14B, play a central role. Conclusion: In this study, we found integrative evidence for the possible role of novel candidate genes and pathways. These genes are involved in mechanisms of synaptic plasticity, which have been associated with several psychiatric disorders. Analysis of epigenetic factors have a great potential for the identification of the mechanisms involved in the pathogenesis of MDD, taking into account their possible role in the interaction between genetic factors and the environment.
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Farwah B. Alam, Yeimy González-Giraldo, Diego Forero
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
September 2022-present © Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Open access articles under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. No commercial re-use is allowed.
January-September 2022 © The authors. Open access articles under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. No commercial re-use is allowed.
January 2014-December 2021 © Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Open access articles under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.